Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to Enanta Pharmaceuticals Fiscal First Quarter Financial Results Conference Call. At this time, all participants are on a listen-only mode. There will be a question-and-answer session at the end of the prepared remarks. Please be advised that this call is being recorded. I would now like to turn the call over to Jennifer Vera, Investor Relations. Please go ahead. Thank you, Operator, and thanks to everyone for joining us this afternoon. The news release with our fiscal first quarter financial results was issued this afternoon and is available on our website. Making remarks on today's call are Dr. Jay Lulli, President and Chief Executive Officer, and Paul Mellott, our Chief Financial Officer. Dr. Scott Rottinghaus, our Chief Medical Officer, and Dr. Tara Kiefer, our Chief Product Strategy Officer, will be available during the Q&A portion of this call. Before we begin with our formal remarks, we want to remind you that we will be making forward-looking statements, which may include our plans and expectations with respect to our research and development pipeline and financial projections, all of which involve certain assumptions and risks beyond our control that could cause our actual developments and results to differ materially from those statements. A description of these risks is in our most recent form, 10-K, and our other periodic reports filed with the SEC. Enanta does not undertake any obligation to update any forward-looking statements made during this call. With that, I'd like to turn the call over to Dr. Jay Lulli, President and CEO. Jay? Thank you, Jennifer, and good afternoon, everyone. In the first quarter of 2024, Enanta began an important year, which has the potential to advance our programs in both virology and immunology and...